Company remains on track to initiate the clinical trial in Q4 of 2023
ROCKVILLE, Md., Sept. 25, 2023 /PRNewswire/ Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage.
Shuttle Pharmaceuticals (SHPH) Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 166,300 shares, an increase of 43.2% from the July 15th total of 116,100 shares. Approximately 2.6% of the shares of the stock […]